Core Viewpoint - The company, 3SBio Inc. (01530.HK), announced plans to spin off its subsidiary, Mandiant, for an independent listing on the Hong Kong Stock Exchange, subject to various approvals and considerations [1] Group 1 - The proposed spin-off of Mandiant is contingent upon approvals from relevant authorities, final decisions from the boards of both the company and Mandiant, as well as market and other factors [1] - The completion of the spin-off is not guaranteed, indicating potential uncertainties surrounding the process [1] - Shareholders and other investors are advised to exercise caution when trading the company's securities during this period [1]

Core Viewpoint - The company plans to spin off its subsidiary Mandi Group and list it independently on the Hong Kong Stock Exchange, which is expected to enhance shareholder value and provide greater market visibility for Mandi [1][2]. Group 1: Spin-off Details - The proposed spin-off will involve a distribution of Mandi shares to existing shareholders based on their ownership percentage in the company, along with a global offering of new Mandi shares [1]. - Mandi submitted its application to the Stock Exchange on November 20, 2025, for the approval of its shares to be listed and traded on the main board [1]. Group 2: Ownership Structure - As of the announcement date, Mandi is beneficially owned by the company (approximately 87.16%), along with other entities including Intai Management Limited, Mandi Group Limited, GL Wecan Investment IV L.P., and Alibaba Health (Hong Kong) Technology Co., Ltd. [2]. Group 3: Company Profile - Mandi is recognized as a leading professional consumer pharmaceutical company in China, focusing on comprehensive and long-term solutions for skin health and weight management [2]. - The company has established a leadership position in the hair health sector within the broader skin health industry, having launched the first 5% minoxidil solution under the Mandi® brand in 2001 [2]. - In 2024, Mandi plans to introduce a second-generation minoxidil product, the Mandi® 5% minoxidil foam [2].

Group 1 - Company plans to spin off its subsidiary Mandi Group and list it independently on the Hong Kong Stock Exchange [1] - The proposed spin-off will involve a distribution of Mandi shares to shareholders based on their ownership percentage and a global offering of new Mandi shares [1] - Mandi submitted its application to the Stock Exchange on November 20, 2025, for the approval of its shares to be listed and traded [1] Group 2 - Mandi is primarily owned by the company and several other entities, holding approximately 87.16%, 3.38%, 2.80%, 4.00%, and 2.65% of the equity respectively [2] - The spin-off group is recognized as a leading professional consumer pharmaceutical company in China, focusing on skin health and weight management solutions [2] - Mandi has established a leadership position in the hair health sector within the broader skin health industry, launching the first 5% minoxidil solution in 2001 and planning to introduce a second-generation minoxidil foam product in 2024 [2]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 並於香港聯合交易所有限公司主板獨立上市 本 公 司 建 議 將 本 公 司 附 屬 公 司 蔓 迪 股 份 分 拆 並 於 聯 交 所 主 板 獨 立 上 市。建 議 分 拆（倘 進 行）預計將通過（i）本公司按董事會為確定股東權利而釐定的記錄日 期，根 據 股 東 各 自 於 本 公 司 的 持 股 比 例，以 實 物 分 派 方 式 向 股 東 分 派 其 持 有 的 蔓迪全部股份及（ii）蔓 迪 新 股 的 全 球 發 售，包 括 香 港 公 開 發 售 及 國 際 發 售。 根據上市規則第15項 應 用 指 引，蔓 迪 股 份 於 聯 交 所 獨 立 上 市，構 成 本 公 司 對 蔓 迪 的 分 拆。聯 交 所 ...

Core Viewpoint - The Hong Kong stock market continues to adjust, with the Hang Seng Index showing mixed performance, while the innovative drug sector demonstrates resilience, as evidenced by the performance of the Hong Kong Stock Connect Innovative Drug ETF (520880) which ended a four-day decline [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw a price increase of 1.79% during the day, successfully ending its previous four-day decline [1]. - The ETF's performance is supported by major leading stocks in the innovative drug sector, with notable gains from companies such as Innovent Biologics, which rose by 2.84%, and others like China Biologic Products and Kintor Pharmaceutical, which increased by over 1% [1]. Group 2: Investment Insights - Following a strong rebound of nearly 7% the previous week, the ETF has returned to a state of fluctuation, currently trading at a near four-month low, indicating a potential area for cost-effective investment [3]. - The fund manager, Feng Chen, suggests that each significant pullback in the innovative drug sector presents an opportunity for accumulation [3]. - The innovative drug sector is undergoing a notable correction since early September, attributed to market style shifts and the return to more realistic expectations regarding business development (BD) rhythms and amounts [3]. Group 3: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) is characterized by three unique advantages: it is purely focused on innovative drug companies, has a significant concentration of leading stocks with over 71% weight in the top ten holdings, and maintains better risk control by reducing the weight of less liquid component stocks [3][4]. - The top ten holdings in the ETF account for 71.51% of the total weight, showcasing the dominance of leading companies in the sector [4]. - As of November 19, the ETF has a scale of 2.12 billion HKD and an average daily trading volume of 464 million HKD since its inception, making it the largest and most liquid ETF tracking the same index [4].

Company Background - Founded in 1993, the company is a leading biopharmaceutical firm in China with extensive experience in R&D, production, and sales of biological drugs. It has developed a rich product portfolio and pipeline in various therapeutic areas including nephrology, hematology, oncology, autoimmune diseases, and dermatology [1] - The company has strong domestic commercialization capabilities, with core products such as TPIAO, EPO, Yisaipu, and Mandi holding high market shares, driving continuous revenue growth [1] Oncology Focus - The SSGJ-707 molecule is expected to become a cornerstone therapy in global cancer immunotherapy, with multiple first-in-class (FIC) molecules entering clinical stages. A significant licensing agreement with Pfizer was established in May-July 2025, where Pfizer will pay $1.4 billion upfront and up to $4.8 billion in milestone payments, setting a record for domestic PD-(L)1/VEGF dual antibodies [1][2] - The PD-(L)1 inhibitors face challenges in cold tumors and efficacy improvements, but the dual antibody approach has shown potential in head-to-head trials against existing therapies, indicating a market potential exceeding $100 billion [1] Clinical Development Plans - Pfizer's strategy for SSGJ-707 includes launching seven global clinical trials, positioning it as a foundational therapy across various cancers. Upcoming trials include 1L NSCLC Phase III, 1L mCRC Phase III, and others, with plans to explore over 10 additional indications by 2026 [2] - The potential market for SSGJ-707 could cover over 350,000 patients in the U.S., indicating a substantial market opportunity [2] Commercialization Strength - The company has a strong commercial capability with its flagship product TPIAO projected to generate revenue of 5.06 billion yuan in 2024. TPIAO is the only commercialized rhTPO globally and is highly recommended in treatment guidelines [3] - Despite competitive pressures, the company maintains a leading position in the rhEPO market, with expected sales of 1.019 billion yuan from its dual-brand strategy in 2024, capturing a 42% market share [3] Financial Projections - Revenue forecasts for the company are estimated at 18.52 billion yuan in 2025, 11.55 billion yuan in 2026, and 11.78 billion yuan in 2027, with net profits projected at 9.77 billion yuan, 3.72 billion yuan, and 3.28 billion yuan respectively. The company is rated with a strong recommendation based on these projections [4]

Core Viewpoint - The report from China Merchants Securities gives a "strong buy" rating for Sangfor Pharmaceutical (01530), highlighting the potential of its PD-(L)1/VEGF dual antibody, SSGJ-707, as a cornerstone drug in next-generation immuno-oncology (IO) treatment [1][2] Company Background - Sangfor Pharmaceutical, established in 1993, is a leading biopharmaceutical company in China with extensive experience in R&D, production, and sales of biological drugs [1] - The company has a solid product pipeline in various therapeutic areas, including nephrology, oncology, and autoimmune diseases, and maintains a strong domestic commercialization capability [1] Product Pipeline and Clinical Development - SSGJ-707 is expected to become a significant player in global tumor immunotherapy, with multiple first-in-class (FIC) molecules entering clinical stages [2] - A major licensing agreement with Pfizer includes a $1.4 billion upfront payment, up to $4.8 billion in milestone payments, and a $100 million equity investment, marking a record for domestic PD-(L)1/VEGF dual antibodies [2] - Pfizer plans to initiate seven global clinical trials for SSGJ-707, positioning it as a cornerstone therapy across various cancer types [3] Commercialization and Revenue Growth - Sangfor's core product, TPIAO, is projected to generate revenue of 5.06 billion yuan in 2024, with growth potential due to new indications and strong market positioning [4] - The company maintains a leading position in the rhEPO market, expecting combined sales of 1.019 billion yuan from its dual brands in 2024, capturing a 42% market share [4] Financial Forecast and Investment Rating - Revenue projections for Sangfor from 2025 to 2027 are 18.52 billion, 11.55 billion, and 11.78 billion yuan, with net profits of 9.77 billion, 3.72 billion, and 3.28 billion yuan, respectively [5] - The company is assigned a "strong buy" rating based on its growth potential and robust financial outlook [5]

恒生医疗冲高回落后全天震荡下行，截至收盘下跌1.77%。其中三生制药大跌3.32%，中国生物、石药 集团、药明生物等多股跌幅均在1%上方；百济神州逆势上涨1.02%。 开盘后直线跳水，随后全天震荡下行，截至收盘恒生指数大跌1.72%，日线三连跌的同时跌破所有短期 均线。恒生科技跌幅居前，大消费、医疗、科技、银行、互联网等紧随其后。 恒生科技低开低走后全天弱势，截至收盘下跌1.81%，小鹏汽车大跌10.47%，联想集团下跌4.16%，比 亚迪股份、地平线机器人、蔚来、快手等多股跌幅均在3%上方。 大消费低开低走手段1.79%，其中零跑汽车下跌4.65%，康方生物下跌3.7%，京东健康下跌3.46%，理想 汽车、泡泡玛特等多股跌幅均在2%上方。 银行低开低走，日线三连跌，截至收盘下跌1.55%。其中重庆农村商业银行大跌344%，渣打银行、中信 银行、招商银行、汇丰银行、青岛银行等超10只个股跌幅均在2%上方。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整性亦 不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。 Mandi Inc. 蔓迪國際 （於開曼群島註冊成立的有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求而刊發， 僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣下知悉、 接納並向Mandi Inc.（蔓迪国际）（「本公司」）、其獨家保薦人、整體協調人、顧問或承銷團成員表示同意： 本公司招股章程根據香港法例第32章 公 司（清 盤 及 雜 項 條 文）條 例 送 呈 香 港 公 司 註 冊 處 處 長 登 記 前，本 公 司 不 會 向 香 港 公 眾 人 士 提 出 要 約 或 邀 請。倘 於 適 當 時 候 向 香 港 公 眾 人 士 提 出 要 約 或 邀 請，有 意 投 資 者 務 請 僅 依 據 呈 交 香港公司註冊處處長註冊的本公司 ...

Investment Rating - The report gives a "Strong Buy" rating for the company [2]. Core Views - The PD-(L)1/VEGF dual antibody is positioned as a core drug for next-generation immuno-oncology treatments, with the SSGJ-707 molecule showing unique design and early clinical data indicating its potential as a best-in-class (BIC) candidate. The collaboration with Pfizer, involving an upfront payment of $1.4 billion and potential milestone payments of up to $4.8 billion, reflects the recognition of SSGJ-707's potential and the company's R&D capabilities [1][8][48]. - The company's financial performance is stable, with a well-structured product pipeline and strong long-term growth drivers [1][8]. Summary by Sections Company Overview - Established in 1993, the company is a leading biopharmaceutical firm in China, focusing on R&D, production, and sales of biological drugs. It has developed a rich product and pipeline portfolio across various therapeutic areas, including nephrology, oncology, autoimmune diseases, and dermatology [13][16]. Oncology Pipeline - The SSGJ-707 is expected to become a cornerstone in global cancer immunotherapy, with multiple first-in-class (FIC) molecules entering clinical stages. The collaboration with Pfizer is a significant milestone, with substantial financial backing and a strategic focus on expanding clinical trials [1][8][37]. - Clinical data for SSGJ-707 shows promising efficacy and safety profiles, with high overall response rates (ORR) in various cancer types, indicating its potential to address unmet medical needs in oncology [1][8][37][38]. Autoimmune Pipeline - The company has several pipelines nearing commercialization, with notable advancements in clinical trials for various autoimmune treatments. The IL-17A monoclonal antibody SSGJ-608 and IL-1β monoclonal antibody SSGJ-613 have received NDA acceptance, indicating progress towards market entry [8][19]. Commercialization Capability - The company demonstrates strong commercialization capabilities, with core products maintaining high market shares. The flagship product, TPIAO, is expected to generate significant revenue, supported by new indications and stable pricing strategies [8][19][30]. - The company is also expanding its product portfolio in the erythropoiesis-stimulating agent market, maintaining a leading position despite competitive pressures [8][19]. Financial Projections - Revenue projections for 2025-2027 are estimated at 185.2 billion, 115.5 billion, and 117.8 billion CNY, respectively, with corresponding net profits of 97.7 billion, 37.2 billion, and 32.8 billion CNY. The report anticipates a significant increase in revenue in 2025, followed by a decline in subsequent years [7][8].